ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of GBP 27.91 billion. The enterprise value is 28.16 billion.

Market Cap	27.91B
Enterprise Value	28.16B

Important Dates

The last earnings date was Thursday, January 23, 2025.

Earnings Date	Jan 23, 2025
Ex-Dividend Date	Feb 13, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.02%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.91M

Valuation Ratios

The trailing PE ratio is 27.98.

PE Ratio	27.98
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	17.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.89, with an EV/FCF ratio of 25.33.

EV / Earnings	28.23
EV / Sales	7.11
EV / EBITDA	19.89
EV / EBIT	22.39
EV / FCF	25.33

Financial Position

The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.16.

Current Ratio	3.33
Quick Ratio	1.74
Debt / Equity	0.16
Debt / EBITDA	0.48
Debt / FCF	0.60
Interest Coverage	65.73

Financial Efficiency

Return on equity (ROE) is 25.65% and return on invested capital (ROIC) is 16.30%.

Return on Equity (ROE)	25.65%
Return on Assets (ROA)	13.89%
Return on Invested Capital (ROIC)	16.30%
Return on Capital Employed (ROCE)	24.81%
Revenue Per Employee	394,324
Profits Per Employee	99,943
Employee Count	9,980
Asset Turnover	0.70
Inventory Turnover	1.91

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.00% in the last 52 weeks. The beta is 0.69, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	+25.00%
50-Day Moving Average	240.47
200-Day Moving Average	226.21
Relative Strength Index (RSI)	47.57
Average Volume (20 Days)	572

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.45

Income Statement

In the last 12 months, ResMed had revenue of GBP 3.94 billion and earned 997.43 million in profits. Earnings per share was 6.77.

Revenue	3.94B
Gross Profit	2.32B
Operating Income	1.25B
Pretax Income	1.23B
Net Income	997.43M
EBITDA	1.37B
EBIT	1.25B
Earnings Per Share (EPS)	6.77

Full Income Statement

Balance Sheet

The company has 416.91 million in cash and 670.76 million in debt, giving a net cash position of -253.84 million.

Cash & Cash Equivalents	416.91M
Total Debt	670.76M
Net Cash	-253.84M
Net Cash Per Share	n/a
Equity (Book Value)	4.20B
Book Value Per Share	28.57
Working Capital	1.58B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.18 billion and capital expenditures -67.54 million, giving a free cash flow of 1.11 billion.

Operating Cash Flow	1.18B
Capital Expenditures	-67.54M
Free Cash Flow	1.11B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.02%, with operating and profit margins of 31.67% and 25.35%.

Gross Margin	59.02%
Operating Margin	31.67%
Pretax Margin	31.16%
Profit Margin	25.35%
EBITDA Margin	34.75%
EBIT Margin	31.67%
FCF Margin	28.25%

Dividends & Yields

This stock pays an annual dividend of 1.58, which amounts to a dividend yield of 0.66%.

Dividend Per Share	1.58
Dividend Yield	0.66%
Dividend Growth (YoY)	7.06%
Years of Dividend Growth	3
Payout Ratio	23.76%
Buyback Yield	-0.02%
Shareholder Yield	0.64%
Earnings Yield	3.57%
FCF Yield	3.98%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.76.

Altman Z-Score	12.76
Piotroski F-Score	n/a